SCHEMBL6418336

SCHEMBL6418336

NN=C(c1ccc(O)cc1)c1nc2nonc2nc1Nc1ccc(F)c(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
TP53 P04637 2/20 0.39
POLB P06746 1/20 0.39
CCR2 P41597 1/20 0.38
CCR5 P51681 1/20 0.38
BRAF P15056 1/20 0.38
MAPK1 P28482 1/20 0.38
GRM4 Q14833 1/20 0.38
ABCG2 Q9UNQ0 1/20 0.37
EGFR P00533 4/20 0.36
KDR P35968 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
HPGD P15428 1/20 0.36
CSNK2A1 P68400 4/20 0.36
ERBB2 P04626 1/20 0.36
CSNK2A2 P19784 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6418314 1.00 MAPT (0.39) MAPTSMN1; SMN2TP53POLBCCR2
SCHEMBL6432179 0.91 MAPT (0.38) MAPTSMN1; SMN2TP53POLBCCR2
SCHEMBL6432166 0.91 MAPT (0.38) MAPTSMN1; SMN2TP53POLBCCR2
SCHEMBL6417031 0.90 CSNK2A1 (0.44) MAPTSMN1; SMN2TP53POLBABCG2
SCHEMBL6417016 0.90 CSNK2A1 (0.44) MAPTSMN1; SMN2TP53POLBABCG2
SCHEMBL6440257 0.89 TP53 (0.41) MAPTSMN1; SMN2TP53POLBCCR2
SCHEMBL6440251 0.89 TP53 (0.41) MAPTSMN1; SMN2TP53POLBCCR2
SCHEMBL6414240 0.87 MAPT (0.37) MAPTSMN1; SMN2TP53POLBCCR2
SCHEMBL6414239 0.87 MAPT (0.37) MAPTSMN1; SMN2TP53POLBCCR2
SCHEMBL6418260 0.86 TP53 (0.42) MAPTSMN1; SMN2TP53POLBCCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MAPT 4420/4885SMN1; SMN2 4369/4885TP53 4485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.